Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Photocure ASA (PHO.OL)
NOK58.00
+0.20 (+0.35%)
NO OSL Healthcare Biotechnology
Address
Hoffsveien 4 275
Oslo, NO
Oslo, NO
CEO
Daniel Schneider
Website
photocure.com
IPO
2000-05-30
ISIN NO0010000045
Also trades on
London Stock Exchange · 0IMT.L (NOK)
Oslo Stock Exchange · PHO.OL (NOK)
Other OTC · PHCUF (USD)
Description
Photocure ASA is a specialized pharmaceutical enterprise focused on the development, manufacturing, commercialization, and distribution of medicinal products. Its operational footprint extends across multiple European nations, including the Nordic region, Germany, France, Austria, the United Kingdom, the Netherlands, and Italy, in addition to the United States. The company's primary offering, Hexvix/Cysview, aids in the identification and ongoing management of bladder cancer. Moreover, Photocure is actively progressing Cevira, a therapeutic agent in development targeting human papilloma virus (HPV) infections and pre-cancerous lesions of the cervix. The firm distributes its products to pharmaceutical wholesalers, pharmacies, and healthcare institutions through collaborative licensing arrangements. Founded in 1993, Photocure ASA maintains its corporate headquarters in Oslo, Norway.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
NOK58.00
+0.20 (+0.35%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
71.8K
Beta
0.36
Float Shares
25.38M
Free Float %
95.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -7.16% | +5.83% | +0.47% | +8.18% | -11.68% | +27.51% | +20.95% | -48.95% | +48.71% | -57.09% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
58.00
DCF (Unlevered)
114.67
+97.7%
DCF (Levered)
71.89
+23.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
7.13
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+1.4% Q1'26: +111.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+66.5% ★ Q1'26: +3,570.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+20.0% ★ Q1'26: -2.5% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+20.7% ★ Q1'26: +49.2% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+44.9% ★ Q1'26: +103.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-1.6% ★ Q1'26: -0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× ★ Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2008 actual |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
102.22M
est: 116.55M (-12.3%)
|
48.43M
est: 440.76M (-89.0%)
|
177.36M
est: 134.66M (+31.7%)
|
115.57M
est: 103.19M (+12.0%)
|
133.82M
est: 97.08M (+37.8%)
|
83.62M
est: 80.15M (+4.3%)
|
134.72M
est: 126.23M (+6.7%)
|
143.63M
est: 137.63M (+4.4%)
|
150.91M
est: 149.30M (+1.1%)
|
181.51M
est: 178.78M (+1.5%)
|
281.56M
est: 237.39M (+18.6%)
|
256.48M
est: 250.50M (+2.4%)
|
360.54M
est: 352.63M (+2.2%)
|
393.13M
est: 396.12M (-0.8%)
|
500.66M
est: 513.58M (-2.5%)
|
525.39M
est: 510.80M (+2.9%)
|
532.58M
est: 532.47M (+0.0%)
|
630.67M
586.36M – 707.96M
+18.4% YoY
|
678.64M
650.06M – 734.76M
+7.6% YoY
|
706.08M
704.62M – 707.54M
+4.0% YoY
|
| EBITDA |
-67.12M
est: -67.34M (+0.3%)
|
-75.05M
est: -189.40M (+60.4%)
|
23.99M
est: 97.95M (-75.5%)
|
-43.96M
est: 22.91M (-291.9%)
|
-31.67M
est: -34.15M (+7.3%)
|
-66.98M
est: -32.03M (-109.1%)
|
-18.09M
est: -51.99M (+65.2%)
|
-8.01M
est: -21.25M (+62.3%)
|
-33.10M
est: 26.78M (-223.6%)
|
-10.49M
est: -30.91M (+66.1%)
|
48.47M
est: -29.02M (+267.0%)
|
-15.77M
est: 60.59M (-126.0%)
|
16.82M
est: 98.84M (-83.0%)
|
-20.95M
est: 173.99M (-112.0%)
|
63.75M
est: 248.58M (-74.4%)
|
74.09M
est: 247.23M (-70.0%)
|
139.51M
est: 257.72M (-45.9%)
|
305.25M
283.81M – 342.66M
+18.4% YoY
|
328.47M
314.64M – 355.64M
+7.6% YoY
|
341.75M
341.05M – 342.46M
+4.0% YoY
|
| EBIT |
-68.65M
est: -97.76M (+29.8%)
|
-62.95M
est: -253.28M (+75.1%)
|
22.67M
est: -24.14M (+193.9%)
|
-20.69M
est: 5.75M (-459.9%)
|
-31.01M
est: -54.00M (+42.6%)
|
-68.44M
est: -32.36M (-111.5%)
|
-21.99M
est: -52.53M (+58.1%)
|
-15.86M
est: -35.52M (+55.3%)
|
-45.20M
est: 9.66M (-568.0%)
|
-23.70M
est: -54.51M (+56.5%)
|
42.74M
est: -49.91M (+185.6%)
|
-26.20M
est: 39.37M (-166.5%)
|
-7.83M
est: 64.22M (-112.2%)
|
-45.33M
est: 113.04M (-140.1%)
|
36.07M
est: 226.77M (-84.1%)
|
45.29M
est: 225.54M (-79.9%)
|
110.04M
est: 235.11M (-53.2%)
|
278.47M
258.91M – 312.60M
+18.4% YoY
|
299.65M
287.03M – 324.43M
+7.6% YoY
|
311.77M
311.12M – 312.41M
+4.0% YoY
|
| Net Income |
-64.38M
est: -83.00M (+22.4%)
|
312.38M
est: -242.01M (+229.1%)
|
18.09M
est: 95.44M (-81.0%)
|
-7.51M
est: 13.87M (-154.2%)
|
-47.90M
est: -7.06M (-578.9%)
|
-58.95M
est: -39.55M (-49.1%)
|
-36.18M
est: -64.19M (+43.6%)
|
35.31M
est: -39.39M (+189.6%)
|
-34.70M
est: 38.40M (-190.3%)
|
-36.71M
est: -41.84M (+12.3%)
|
31.83M
est: -48.33M (+165.9%)
|
-22.40M
est: 29.32M (-176.4%)
|
-30.90M
est: 47.83M (-164.6%)
|
-71.86M
est: 84.20M (-185.3%)
|
979.0K
est: 12.84M (-92.4%)
|
-4.81M
est: -5.33M (+9.8%)
|
-1.52M
est: -6.60M (+77.0%)
|
53.00M
35.13M – 87.12M
+903.4% YoY
|
70.08M
47.04M – 93.13M
+32.2% YoY
|
78.00M
27.30M – 88.56M
+11.3% YoY
|
| SGA |
54.52M
est: 44.52M (+22.5%)
|
34.44M
est: 172.49M (-80.0%)
|
44.08M
est: 7.64M (+477.1%)
|
61.36M
est: 27.13M (+126.2%)
|
70.19M
est: 47.23M (+48.6%)
|
68.42M
est: 57.96M (+18.1%)
|
73.40M
est: 94.07M (-22.0%)
|
79.93M
est: 79.92M (+0.0%)
|
96.43M
est: 86.94M (+10.9%)
|
121.30M
est: 116.29M (+4.3%)
|
148.74M
est: 159.72M (-6.9%)
|
187.81M
est: 137.02M (+37.1%)
|
259.87M
est: 223.50M (+16.3%)
|
303.43M
est: 393.43M (-22.9%)
|
319.87M
est: 361.67M (-11.6%)
|
355.04M
est: 359.71M (-1.3%)
|
380.15M
est: 374.97M (+1.4%)
|
444.12M
412.92M – 498.55M
+18.4% YoY
|
477.90M
457.78M – 517.43M
+7.6% YoY
|
497.23M
496.20M – 498.26M
+4.0% YoY
|
| EPS |
-2.91
est: -3.14 (+7.5%)
|
14.16
est: 14.41 (-1.7%)
|
0.84
est: 1.26 (-33.5%)
|
-0.35
est: -3.30 (+89.4%)
|
-2.25
est: -3.70 (+39.1%)
|
-2.78
est: -3.26 (+14.6%)
|
-1.69
est: -0.89 (-89.9%)
|
1.64
est: -0.79 (+308.9%)
|
-1.61
est: -1.75 (+7.7%)
|
-1.70
est: -0.83 (-104.8%)
|
1.46
est: 0.01 (+29,100.0%)
|
-0.91
est: -0.59 (-55.1%)
|
-1.15
est: -0.36 (-220.0%)
|
-2.66
est: -1.78 (-49.0%)
|
0.04
est: 0.47 (-92.4%)
|
-0.17
est: 0.21 (-182.3%)
|
-0.06
est: -0.24 (+76.3%)
|
2.29
1.32 – 3.27
+1,054.4% YoY
|
2.63
1.76 – 3.49
+14.7% YoY
|
1.90
1.02 – 3.32
-27.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
27.22M
OE per share TTM
1.03
Owner's Yield
1.60%
Maintenance CapEx ratio
0.80%
Maint CapEx / Avg PPE
4.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 5 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Small Cap ETF DFIS | 0.00% | 283.9K | 0.39% |
| 2 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 90.0K | 0.22% |
| 3 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 27.3K | 0.28% |
| 4 | Dimensional - International Core Equity Market ETF DFAI | 0.00% | — | 0.18% |
| 5 | Dimensional International Sustainability Core 1 ETF DFSI | 0.00% | — | 0.24% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
1.11M
Shares Outstanding
26.61M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Daniel Schneider | President & Chief Executive Officer | 11M | male |
| Anders Neijber | Chief Medical Officer of Global Medical Affairs, Clinical Development and R&D | 5M | — |
| Erik Dahl | Chief Financial Officer | 4M | male |
| Anja Gossens-von der Heidt | Head of Global Human Resources | 3M | — |
| Priyam Shah | ????Vice President of Investor Relations | — | male |
| Tolv Hillestad | Group Controller | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PHO.OL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
